If all breaks its way, J&J could deliver late November readout for COVID-19 vaccine

The best-case scenario for J&J would put a Phase III readout for its COVID-19 vaccine at the end of November. 

Johnson & Johnson (NYSE:JNJ) said Wednesday that it started its ENSEMBLE study of JNJ-78436735 after interim results from its Phase I/IIa clinical study of the vaccine showed that the safety profile and immunogenicity after a single vaccination supported further development. Results are due to be published in medRxiv “imminently,” according to the company...